M. Heberton

Cutaneous CD4 + small/medium T‐cell lymphoproliferative disorder

C. Pinnix, L. Fayad, J. Gunther, 2020, Skin Lymphoma.

Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

D. Ledesma, P. Nagarajan, V. Prieto, 2021, Journal of cutaneous pathology.

Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma

P. Nagarajan, M. Campbell, J. Curry, 2021, JAAD case reports.

Cutaneous Surgery Outcomes in Patients on Epidermal Growth Factor Receptor Inhibitors

Anisha B. Patel, V. Thomas, Kelly M Wilmas, 2021, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction

Jianjun Gao, D. Ivan, A. Siefker-Radtke, 2021, Frontiers in Oncology.

Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients

Omar Pacha, A. Huen, Meghan M. Heberton, 2021, Supportive Care in Cancer.

A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes.

K. Nelson, Omar Pacha, A. Huen, 2022, Journal of the American Academy of Dermatology.

Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine.

M. Konopleva, K. Bhalla, T. Kadia, 2022, Leukemia research.

Severe de novo pustular psoriasiform immune‐related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma

P. Nagarajan, Toshiyuki Yamamoto, P. Aung, 2021, Journal of cutaneous pathology.

Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment

R. Amaria, R. Miranda, Elizabeth Keiser, 2020, JAAD case reports.

Durvalumab-associated generalized morphea with overlapping vitiligo

J. Tayar, K. Woodman, Woo Cheal Cho, 2022, JAAD case reports.

Pembrolizumab-induced rash in a patient with angiosarcoma

K. Nelson, R. Jahan-Tigh, J. Curry, 2022, JAAD Case Reports.